IL33 and neoplasm: Transgenic expression of IL-33 in B16 or 4T1 tumor cells (20) or in the host (21), as well as exogenous administration of the recombinant protein (22) induce the recruitment of activated (IFN-γ+ CD107+) CD8+ T and NK cells in the TME, which inhibited tumor growth in mice.